AdultPediatricGeriatricDosage Forms & Strengths tablet 0.5mg 1mg 2mg 5mg 10mg 20mg oral concentrate 2mg/mL injectable solution, lactate 5mg/mL injectable solution, decanoate 50mg/mL 100mg/mL Schizophrenia, Psychosis PO Moderate disease, 0.5-2 mg q8-12hr initially Severe disease, 3-5 mg q8-12hr initially; not to exceed 30 mg/day IM lactate (prompt-acting) 2-5 mg q4-8hr PRN; may require q1hr in acute agitation; not to exceed 20 mg/day IM decanoate (depot) Initial: IM dose 10-20 times daily PO dose administered monthly; not to exceed 100 mg; if conversion requires initial dose >100 mg, administer in 2 injections (eg, 100 mg initially, then remainder in 3-7 days) Maintenance: Monthly dose 10-15 times daily PO dose IV (Off-label) May be needed for ICU delirium; use only haloperidol lactate for IV administration; do not use haloperidol decanoate 2-10 mg initially, depending on degree of agitation; if response inadequate, may repeat bolus q15-30min, sequentially doubling initial bolus dose; when calm achieved, administer 25% of last bolus dose q6hr; taper dose after patient is controlled Monitor ECG and QT interval (QT prolongation may occur with cumulative doses ≥35 mg; torsades de pointes reported with single doses ≥20 mg) Tourette Disorder 0.5-2 mg PO q8-12hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr; if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined) Dosage Forms & Strengths tablet 0.5mg 1mg 2mg 5mg 10mg 20mg oral concentrate 2mg/mL injectable solution, lactate 5mg/mL injectable solution, decanoate 50mg/mL 100mg/mL Schizophrenia, Psychosis/Sedation <3 years: Safety and efficacy not established 3-12 years (15-40 kg): 0.25-0.5 mg/day PO divided q8-12hr initially; may be increased by 0.5 mg/day every 5-7 days PRN; maintenance: 0.05-0.15 mg/kg/day PO divided q8-12hr 6-12 years: Lactate (prompt-acting): 1-3 mg IM q4-8hr PRN; not to exceed 0.15 mg/kg/day >12 years: Moderate disease, 0.5-2 mg PO q8-12hr initially; severe disease, 3-5 mg PO q8-12hr; not to exceed 30 mg/day Tourette Disorder <3 years: Safety and efficacy not established 3-12 years: 0.5 mg/day PO initially; dose increased by 0.5 mg every 5-7 days until therapeutic effect achieved, then reduced to lowest effective maintenance level of 0.05-0.075 mg/kg/day PO divided q8-12hr >12 years: 0.5-2 mg PO q8-12hr initially; if severe symptoms necessitate increased dosage, titrate upward to 3-5 mg PO q8-12hr; if patient remains inadequately controlled, daily doses up to 100 mg have been used (safety not determined) Behavioral Disorders <3 years: Safety and efficacy not established 3-12 years: 0.5 mg/day PO initially; dose increased PRN by 0.5 mg every 5-7 days until therapeutic effect achieved, then reduced to lowest effective maintenance level of 0.05-0.075 mg/kg/day PO divided q8-12hr Acute Agitation <12 years: Safety and efficacy not established >12 years: 0.5-3 mg PO, repeated in 1 hour PRN; alternatively, 2-5 mg IM, repeated in 1 hr PRNSchizophrenia, Psychosis PO: Lower initial doses and more gradual adjustments recommended; 0.25-0.5 mg PO q8-12hr initially IM lactate (prompt-acting): Lower adult doses and longer dosing intervals recommended compared with typical adult doses IM decanoate (depot): Lower initial doses and more gradual adjustments recommended; monthly dose 10-15 times daily PO dose IV (off-label): 0.25-0.5 mg IV q4hr; use only lactate (not decanoate) for IV administration; monitor with ECG for prolonged QT interval Not approved for dementia-related psychosis, because of increased risk of cardiovascular or infectious related deaths (see Black Box Warnings) Tourette Disorder Lower initial doses and more gradual adjustments recommended; 0.25-0.5 mg PO q8-12hr initially Dosing Considerations Elderly at higher risk for tardive dyskinesia associated with higher-potency antipsychotic agents such as haloperidol because of higher ratios of dopaminergic blockage to adrenergic/anticholinergic blockadeInteraction CheckerEnter a drug name and haloperidolNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (14)amisulprideamisulpride, haloperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.disopyramidedisopyramide and haloperidol both increase QTc interval. Contraindicated.eliglustathaloperidol increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.flibanserinhaloperidol will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur.ibutilidehaloperidol and ibutilide both increase QTc interval. Contraindicated.indapamidehaloperidol and indapamide both increase QTc interval. Contraindicated.lefamulinlefamulin will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.lomitapidehaloperidol increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.lonafarnibhaloperidol will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated. pentamidinehaloperidol and pentamidine both increase QTc interval. Contraindicated.pimozidehaloperidol and pimozide both increase QTc interval. Contraindicated.procainamidehaloperidol and procainamide both increase QTc interval. Contraindicated.quinidinequinidine and haloperidol both increase QTc interval. Contraindicated.sotalolhaloperidol and sotalol both increase QTc interval. Contraindicated.Serious - Use Alternative (145)abametapirabametapir will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.adagrasibadagrasib, haloperidol. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.amiodaroneamiodarone and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylineamitriptyline and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.amoxapineamoxapine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.anagrelideanagrelide and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.apomorphinehaloperidol decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.arsenic trioxidearsenic trioxide and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineartemether/lumefantrine will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.haloperidol and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.avapritinibhaloperidol will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of avapritinib with moderate CYP3A4 inhibitors. If unable to avoid, reduce avapritinib starting dose. See drug monograph Dosage Modifications.axitinibhaloperidol increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, haloperidol. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.bosutinibhaloperidol increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.bromocriptinehaloperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphinebuprenorphine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.cabergolinehaloperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybateshaloperidol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.carbamazepinecarbamazepine will decrease the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.ceritinibceritinib and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.ceritinib will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.chloramphenicolchloramphenicol will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.chlorpromazinechlorpromazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.citalopramcitalopram will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.citalopram and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.clarithromycinclarithromycin and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.clarithromycin will increase the level or effect of haloperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipraminehaloperidol will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.clomipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.cobimetinibhaloperidol will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).crizotinibcrizotinib and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of haloperidol by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. desfluranedesflurane and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.desipraminehaloperidol will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.desipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.dofetilidedofetilide and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.dopaminehaloperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.doxepinhaloperidol will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.doxepin and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.dronedaronedronedarone and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.droperidoldroperidol and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.elacestranthaloperidol will increase the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eliglustathaloperidol increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .eliglustat and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.encorafenibencorafenib and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.entrectinibhaloperidol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.haloperidol will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidable, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.50m2. Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5 elimination half-lives.epinephrineepinephrine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicepinephrine racemic and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.eribulineribulin and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects;